ImmusanT upgrading the management ahead of phase 2 celiac vaccine trial
ImmusanT has upgraded its senior staff by appointing Daiichi Sankyo’s SVP for internal medicine therapeutics, Ken Truitt, M.D., as its new chief medical officer. The management is also boosted with new VPs in program management and clinical operations, as well as a new finance director. Company is looking forward to the advancement in development of its treatments for celiac disease and Type 1 diabetes.
Nicotine found to be linked with obesity-fighting ‘beige’ fat in a new discovery
Researchers from the University of Michigan and American University believe that they have uncovered a signaling pat...
